Welcome to our dedicated page for Takeda Pharm SEC filings (Ticker: TAK), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The SEC filings page for Takeda Pharmaceutical Company Limited American Depositary Shares (NYSE: TAK) on Stock Titan provides access to the company’s U.S. regulatory disclosures, primarily furnished on Form 20-F and Form 6-K as a foreign private issuer. Takeda prepares its consolidated financial statements in accordance with International Financial Reporting Standards (IFRS) and uses these filings to report semi-annual and annual results, management guidance and material developments in its business.
Recent Form 6-K submissions include English translations of Takeda’s semi-annual securities report and earnings report (Kessan Tanshin) for the six-month period ended September 30, 2025. These documents present revenue by business area (Gastroenterology, Rare Diseases, Plasma-Derived Therapies, Oncology, Vaccines, Neuroscience and Other) and by geographic region, along with operating profit, net profit, cash flow information and explanations of non-IFRS core measures such as core revenue, core operating profit and core EPS. They also discuss factors affecting performance, including generic erosion of specific products, foreign exchange impacts and changes in product mix.
Takeda’s 6-K filings additionally furnish press releases that describe key R&D and strategic events, such as Phase 3 data for zasocitinib (TAK-279) in plaque psoriasis, longer-term VERIFY and THRIVE results for rusfertide in polycythemia vera, portfolio decisions like discontinuation of cell therapy efforts, and revised forecasts for FY2025 revenue and profit. These exhibits provide context on how clinical outcomes, impairments of intangible assets and strategic partnerships influence Takeda’s financial outlook.
Through Stock Titan, users can review Takeda’s SEC filings as they are posted, while AI-powered tools can help summarize lengthy IFRS financial reports, highlight changes in management guidance, and surface important disclosures related to pipeline programs, impairments, capital allocation and regional performance. This makes it easier to understand how Takeda’s global biopharmaceutical operations and late-stage pipeline are reflected in its official U.S. regulatory documents.
Takeda reported strong Phase 3 results for its investigational oral TYK2 inhibitor zasocitinib (TAK-279) in adults with moderate‑to‑severe plaque psoriasis. In two large global LATITUDE PsO studies, about 70% of patients on zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16, far exceeding placebo and apremilast.
Zasocitinib also drove high rates of deeper responses: over half of treated patients reached PASI 90 at week 16, and roughly one‑third achieved complete skin clearance (PASI 100 and sPGA 0), with responses improving through week 24. More than 90% of responders who stayed on drug at week 40 maintained sPGA 0/1, PASI 75 and PASI 90 through week 60, indicating durable control.
The once‑daily pill showed a safety profile consistent with earlier trials, with treatment‑emergent adverse events in 62.1% of zasocitinib patients versus 46.9% on placebo and 50.5% on apremilast; the most common were upper respiratory infection, nasopharyngitis and acne, and no new safety signals were seen. Takeda plans to begin New Drug Application filings in fiscal 2026, targets a first psoriasis launch in the first half of 2027, and cites combined psoriasis and psoriatic arthritis peak revenue potential of $3‑6B, though these results do not change its full‑year forecast to March 31, 2026.
Takeda Pharmaceutical Company Limited is advancing its leadership transition and Board renewal. The Board will propose CEO-elect Julie Kim as a new internal director at the 150th Ordinary General Meeting of Shareholders on June 24, 2026. If elected, she will be appointed representative director, president & CEO immediately after the meeting, while current representative director, president & CEO Christophe Weber plans to retire from Takeda and its Board on the same day.
Takeda is also reshaping its Board with three new external candidates – Bruce Broussard, Koichiro Kimura and Paul Stoffels – and the planned retirement of six current external directors. All other current Board members are expected to be proposed for re-election. An attachment notes that Julie Kim holds 173,773 ADSs and outlines her prior leadership roles at Shire and Takeda, reinforcing her experience ahead of assuming the top role.
Takeda Pharmaceutical Company Limited is launching the next phase of its global transformation program to boost competitiveness and support multiple upcoming drug launches. The company targets annualized gross savings of more than JPY 200 billion by FY2028, mainly through streamlined corporate functions, simpler processes and better use of technology.
These efficiencies are expected to largely offset investments in launch preparations for medicines such as oveporexton, rusfertide and zasocitinib, as well as late-stage pipeline and technology spending. Takeda currently estimates restructuring expenses of about JPY 150 billion in FY2026, with smaller charges in FY2027 and FY2028. The initiatives are not expected to have a significant impact on the full-year consolidated financial forecast for FY2025.
Takeda Pharmaceutical CEO-elect Julie So-Young Kim has filed an initial ownership report showing beneficial ownership of 324,729 American Depositary Shares. This total includes 150,956 restricted stock units (RSUs), each convertible into one ADS. The RSUs vest in stages: 70,110 on July 1, 2026, 52,218 on July 1, 2027, and 28,628 on July 1, 2028, highlighting a multi-year, equity-based incentive structure aligned with her leadership role.
TAKEDA PHARMACEUTICAL CO LTD Global General Counsel Natalie Anne Marie Furney filed an initial ownership report showing an award of 191,280 restricted stock units (RSUs), each representing a contingent right to receive one American Depositary Share.
The RSUs vest in three equal-time tranches: 63,758 on July 1, 2026, 63,758 on July 1, 2027 and 63,764 on July 1, 2028.
Takeda Pharmaceutical executive Teresa Marie Bitetti, President of the Oncology Business Unit, reports beneficial ownership of 193,148 American Depositary Shares. This total includes 85,802 restricted stock units, each convertible into one ADS.
The RSUs are scheduled to vest in three tranches: 40,056 shares on July 1, 2026, 30,564 shares on July 1, 2027, and 15,182 shares on July 1, 2028, providing a clearly defined equity vesting timeline.
Takeda Pharmaceutical filed an initial ownership report for Global Business Development Officer Marcello Pignagnoli Agosti. He reports direct ownership of 144,608 American Depositary Shares. This total includes 53,850 restricted stock units, each representing one ADS, vesting on July 1, 2026, July 1, 2027, and July 1, 2028 in scheduled installments.
Takeda Pharmaceutical director Yoshiaki Fujimori filed an initial ownership report listing his equity interests in the company. He directly holds 27,865 Ordinary Shares. The filing also notes 8,400 restricted stock units (RSUs), each representing a right to receive one Ordinary Share as they vest.
The RSUs vest on June 1, 2026 (2,100 shares), June 1, 2027 (2,200 shares), June 1, 2028 (2,100 shares) and upon retirement from board service (2,000 shares). Separate Tax Obligation Awards are described as economically equivalent to Ordinary Shares but payable in cash primarily to cover tax obligations at future vesting.
Takeda Pharmaceutical director Emiko Higashi filed an initial ownership report showing equity and award holdings in the company. The filing lists 7,600 American Depositary Shares and 17,800 Ordinary Shares held directly, plus restricted stock units and tax-related awards tied to future vesting.
Footnotes explain that 12,800 restricted stock units each convert into one Ordinary Share, then into American Depositary Shares, vesting on June 1, 2026, 2027, 2028 and upon conclusion of board service. Separate Tax Obligation Awards are each economically equivalent to one Ordinary Share and will be settled in cash at vest primarily to cover tax obligations.
TAKEDA PHARMACEUTICAL CO LTD executive Asuka Miyabashira, President of the Japan Pharma Business Unit, reports direct ownership of 3,000 Ordinary Shares. The position also includes 1,600 restricted stock units (RSUs), which are rights to receive one Ordinary Share each as they vest.
The RSUs vest in tranches of 700 shares on June 1, 2026, 500 shares on June 1, 2027, and 400 shares on June 1, 2028. In addition, Miyabashira holds Tax Obligation Awards that are economically equivalent to Ordinary Shares and are designed to be settled in cash primarily to cover tax obligations at the then-current market price when they vest.